ev3 Inc

ev3 — Foxhollow Technologies — Merger or Acquisition (July 2007)

17 slides from ev3's merger presentation, Jul 23, 2007

  1. Slide 1: Creating a Global Leader in Endovascular Devices

    CREATING A GLOBAL LEADER IN ENDOVASCULAR DEVICES

  2. Slide 2: Forward-Looking Statements

    This presentation contains "forward-looking statements" about ev3 and FoxHollow within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the benefits of the business combination transaction involving ev3 and FoxHoll

  3. Slide 3: Forward-Looking Statements (continued)

    Forward-Looking Statements (continued) The following factors, among others, could cause actual results to differ materially from the anticipated results or other expectations expressed in the forward- looking statement: general business and economic conditions; the ability to obtain governmental app

  4. Slide 4: Stacy Enxing Seng, President, Cardio Peripheral, ev3

    Stacy Enxing Seng President, Cardio Peripheral ev3

  5. Slide 5: Transaction Overview

    Transaction Overview Fourth Quarter of 2007 FoxHollow stockholders, customary closing conditions and anti- trust clearance, including HSR Warburg Pincus and The Vertical Group, together owning 56.8% of ev3 shares, have approved ev3's issuance of shares in connection with the transaction and the amen

  6. Slide 6: Creating a Global Leader in Endovascular Device Market

    Creating a Global Leader in Endovascular Device Market Creates broad competitive position in the growing markets for peripheral vascular and neurovascular products Complementary product offering Leveraging combined experienced sales force Capitalizing on global markets Combined product portfolio wil

  7. Slide 7: Powerful Strategic Logic

    Powerful Strategic Logic Driving revenue growth by increased scope and scale Brings together two experienced sales forces with well-established relationships to leverage selling opportunities Enhanced R&D and clinical research to bring products to market faster Ability to leverage infrastructure to

  8. Slide 8: Powerful Financial Logic

    Powerful Financial Logic Significant Revenue Synergies 2008 revenue of $585-$615 million; EPS of $0.60 - $0.70* 2009 revenue of $700-750 million; EPS of $0.90 - $1.10* Market capitalization of $1.7 billion Projected cost savings in excess of $40 million per year Expense reductions in most cost categ

  9. Slide 9: The Peripheral Market Opportunity

    The Peripheral Market Opportunity Carotid Renals Iliac Tibial/ Lower Leg SFA ev3 Participation 2003 Total Market: $2B >10% ev3 Participation 60% 2005 Total Market: $2.5B Expanding Product Portfolio 70% Combined Company Participation

  10. Slide 10: FoxHollow Overview

    FoxHollow Overview Platform technology for the minimally-invasive treatment of Peripheral Artery Disease (PAD) using a unique disposable catheter-based system to remove plaque from the arteries Product Overview: SilverHawk: Received 510(k) clearance in June 2003 and commenced a formal launch in earl

  11. Slide 11: ev3 is the Ideal Partner for FoxHollow

    ev3 is the Ideal Partner for FoxHollow ev3's infrastructure and product breadth is a complementary fit for FoxHollow ev3's strong international distribution networks can bring FoxHollow's SilverHawk technology to markets outside the U.S. Combination of FoxHollow's innovative technologies with ev3's

  12. Slide 12: Guidance

    Guidance Revenues: 2008: In the range of $585-$615 million 2009: In the range of $700-$750 million Projected EPS*: 2008: In the range of $0.60 - $0.70 2009: In the range of $0.90 - $1.10 Including the impact of new and existing amortization expense, excluding the impact of one-time costs related to

  13. Slide 13: What Does This All Mean?

    What Does This All Mean? At the end of the day, this merger is about driving our commitment to peripheral and neurovascular leadership It is about better meeting the needs of our customers and helping them have even more clinical options to treat their patients It is about building a stronger organi

  14. Slide 14: Creating a Global Leader in Endovascular Devices

    CREATING A GLOBAL LEADER IN ENDOVASCULAR DEVICES "In the end, it is important to remember that we cannot become what we need to be by remaining who we are." ~ Max Depree Congratulations Team!

  15. Slide 15: Important Additional Information for Investors and Stockholders

    Important Additional Information for Investors and Stockholders This communication is being made in respect of the proposed business combination involving ev3 and FoxHollow. In connection with the proposed transaction, ev3 intends to file with the SEC a registration statement on Form S-4, containing

  16. Slide 16: Participants in the Solicitation

    Participants in the Solicitation ev3, FoxHollow and their respective directors and executive officers and other persons may be deemed to be participants in the solicitation of proxies from the stockholders of FoxHollow in respect of the proposed transaction. Information regarding ev3's directors and

  17. Slide 17: Use of Non-GAAP Financial Measures

    Use of Non-GAAP Financial Measures In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), ev3 uses the non-GAAP financial measures, such as "adjusted EPS" as supplemental measures of performance and believes these measures facilitate operat

Foxhollow Technologies — Merger or Acquisition (July 2007) on 6ix